Since the emergence of COVID-19, scientists around the world have focused on understanding the immunopathogenesis of SARS-CoV-2 in order to expedite the development of vaccines and treatments to combat this rapidly spreading and deadly contagion.

It has been well-documented that SARS-CoV-2 infects human cells by attaching to the ACE2 receptor, a transmembrane protein found predominantly on respiratory epithelial cells. Spike proteins that cover the surface of SARS-CoV-2 bind to ACE2 and mediate viral entry into cells.

A team led by Dr. Michael Diamond at Washington University in St. Louis, Missouri has developed a panel of murine monoclonal antibodies that bind to a variety of epitopes of the SARS-CoV-2 spike protein with varying ability to neutralize SARS-CoV-2 and inhibit attachment of the virus to the ACE-2 receptor. The Diamond Lab used these antibodies to characterize the antigenicity of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein, demonstrating that the spike protein produced by the vaccine expresses and displays epitopes targeted by the neutralizing antibodies (Hassan et al 2020, Cell).

To further advance their COVID-19 research, the Diamond Lab is partnering with Bio X Cell to grow and purify large quantities of these anti-spike protein antibodies. The researchers hope to test the antibodies in SARS-CoV-2 mouse models to better understand the biology of SARS-CoV-2 and how COVID-19 therapeutic antibodies function.

For over 20 years, Bio X Cell has been supplying high quality in vivo functional grade antibodies to facilitate research findings. In the sprint to combat COVID-19, Bio X Cell is proud to join the global scientific community by providing antibody production and purification services from pre-existing hybridomas with fast turnaround times and unmatched pricing.

Our expertise in antibody production can help you to accelerate breakthroughs in COVID-19 research. All custom products include the following features:

  • Suitability for in vivo Pre-Clinical Research
  • Endotoxin Level < 2EU/mg
  • Purity >95%
  • Preservative, Stabilizer and Carrier
  • Protein Free
  • Isotype Determination*
  • Antibody Aggregation Screening*
  • Murine Pathogen Screening*
  • On-site Cell Line Storage*

 

In addition to contract services, we offer a catalog of over 300 antibodies formulated specifically for in vivo pre-clinical research. These antibodies cover a wide range of research areas including immunology, oncology, and more.

* Services offered with an additional fee.

 

Bio X Cell Joins Global Fight to Defeat COVID-19

Tags

  • Category: News

Since the emergence of COVID-19, scientists around the world have focused on understanding the immunopathogenesis of SARS-CoV-2 in order to expedite the development of vaccines and treatments to combat this rapidly spreading and deadly contagion.

It has been well-documented that SARS-CoV-2 infects human cells by attaching to the ACE2 receptor, a transmembrane protein found predominantly on respiratory epithelial cells. Spike proteins that cover the surface of SARS-CoV-2 bind to ACE2 and mediate viral entry into cells.

A team led by Dr. Michael Diamond at Washington University in St. Louis, Missouri has developed a panel of murine monoclonal antibodies that bind to a variety of epitopes of the SARS-CoV-2 spike protein with varying ability to neutralize SARS-CoV-2 and inhibit attachment of the virus to the ACE-2 receptor. The Diamond Lab used these antibodies to characterize the antigenicity of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein, demonstrating that the spike protein produced by the vaccine expresses and displays epitopes targeted by the neutralizing antibodies (Hassan et al 2020, Cell).

To further advance their COVID-19 research, the Diamond Lab is partnering with Bio X Cell to grow and purify large quantities of these anti-spike protein antibodies. The researchers hope to test the antibodies in SARS-CoV-2 mouse models to better understand the biology of SARS-CoV-2 and how COVID-19 therapeutic antibodies function.

For over 20 years, Bio X Cell has been supplying high quality in vivo functional grade antibodies to facilitate research findings. In the sprint to combat COVID-19, Bio X Cell is proud to join the global scientific community by providing antibody production and purification services from pre-existing hybridomas with fast turnaround times and unmatched pricing.

Our expertise in antibody production can help you to accelerate breakthroughs in COVID-19 research. All custom products include the following features:

  • Suitability for in vivo Pre-Clinical Research
  • Endotoxin Level < 2EU/mg
  • Purity >95%
  • Preservative, Stabilizer and Carrier
  • Protein Free
  • Isotype Determination*
  • Antibody Aggregation Screening*
  • Murine Pathogen Screening*
  • On-site Cell Line Storage*

In addition to contract services, we offer a catalog of over 300 antibodies formulated specifically for in vivo pre-clinical research. These antibodies cover a wide range of research areas including immunology, oncology, and more.

* Services offered with an additional fee.

Back to News

Meet Our Leaders

Learn more about the team behind the gold standard in vivo antibodies.

Discover Bio X Cell

Learn more about our proven expertise and comprehensive antibody solutions.

See Our Impact

Discover the Bio X Cell Fund’s mission to improve the health of our community

Explore Our Latest

See our latest articles and whitepapers for scientific insights and ideas

Don’t see what you need?

Consult With Bio X Cell to Enable Your Next Breakthrough Discovery

Whether you need antibody customization or high-volume production, Bio X Cell is committed to advancing your therapeutic innovations.

Contact Us